Forecasting drug utilization and expenditure in a metropolitan health region

[1]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[2]  S. Brophy,et al.  Interventions for latent autoimmune diabetes (LADA) in adults. , 2011, The Cochrane database of systematic reviews.

[3]  Thomas Kahan,et al.  Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. , 2010, Health policy.

[4]  Jonathan Cylus,et al.  Health spending projections through 2019: the recession's impact continues. , 2010, Health affairs.

[5]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[6]  S. Connolly,et al.  Effect of dronedarone on cardiovascular events in atrial fibrillation. , 2009, The New England journal of medicine.

[7]  P. Zimetbaum.  Dronedarone for atrial fibrillation--an odyssey. , 2009, The New England journal of medicine.

[8]  M. Boman,et al.  Economic consequences to society of pandemic H1N1 influenza 2009 - preliminary results for Sweden. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[9]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[10]  A. Exter.  European Commission takes on Big Pharma , 2009, The Lancet.

[11]  G. Steineck,et al.  Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden , 2009, Diabetologia.

[12]  Salim Yusuf,et al.  Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[13]  B. Jônsson.  Being NICE is not the problem! , 2009, European journal of cancer.

[14]  S. Garattini,et al.  Orphan drug development is not taking off. , 2009, British journal of clinical pharmacology.

[15]  J. Ross,et al.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.

[16]  W. Pikto-Pietkiewicz.  [The effect of dronedarone on the frequency of cardiovascular events in patients with atrial fibrillation - ATHENA studies]. , 2009, Kardiologia polska.

[17]  N. Shah,et al.  Projecting future drug expenditures--2009. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[18]  Bethan Hughes,et al.  2008 FDA drug approvals , 2009, Nature Reviews Drug Discovery.

[19]  A. Haycox,et al.  Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance , 2009, Expert review of pharmacoeconomics & outcomes research.

[20]  J. Wei.  National Health Spending In 2006: A Year Of Change For Prescription Drugs , 2008 .

[21]  J. Góra‐Tybor,et al.  Targeted drugs in chronic myeloid leukemia. , 2008, Current medicinal chemistry.

[22]  P. Hjemdahl,et al.  [A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment]. , 2008, Lakartidningen.

[23]  J. Berenson,et al.  New drugs in multiple myeloma , 2008, Current opinion in supportive and palliative care.

[24]  T. Quinn.  HIV epidemiology and the effects of antiviral therapy on long-term consequences , 2008, AIDS.

[25]  S. Tepper,et al.  Clinical and Preclinical Rationale for CGRP‐Receptor Antagonists in the Treatment of Migraine , 2008, Headache.

[26]  A. Haycox,et al.  Enhancing the rational use of new medicines across European health care systems , 2008, European Journal of Clinical Pharmacology.

[27]  D. Darrow,et al.  Human papillomavirus vaccine: recommendations, issues and controversies , 2008, Current opinion in pediatrics.

[28]  E. Emanuel,et al.  Tier 4 drugs and the fraying of the social compact. , 2008, The New England journal of medicine.

[29]  R. Liang,et al.  Review article: current management of metastatic colorectal cancer – the evolving impact of targeted drug therapies , 2008, Alimentary pharmacology & therapeutics.

[30]  F. Lichtenberg.  Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence from Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003 , 2008, Health economics.

[31]  T. Cross,et al.  Current and future management of chronic hepatitis C infection , 2008, Postgraduate Medical Journal.

[32]  E. Palumbo.  New Drugs for Chronic Hepatitis B: A Review , 2008, American journal of therapeutics.

[33]  N. Motterlini,et al.  Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries. , 2008, Health policy.

[34]  Nilay D Shah,et al.  Projecting future drug expenditures--2008. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[35]  R. Peto,et al.  Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. , 2008, Lancet.

[36]  A. Turpie,et al.  New oral anticoagulants in atrial fibrillation. , 2007, European heart journal.

[37]  U. Schmidt-Erfurth,et al.  Guidance for the treatment of neovascular age-related macular degeneration. , 2007, Acta ophthalmologica Scandinavica.

[38]  J. Lau,et al.  Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. , 2007, JAMA.

[39]  Anders Sundström,et al.  The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months , 2007, Pharmacoepidemiology and drug safety.

[40]  Kieran Murphy,et al.  Effective early warning systems for new and emerging health technologies: Developing an evaluation framework and an assessment of current systems , 2007, International Journal of Technology Assessment in Health Care.

[41]  K. Wolski,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[42]  L. Lesko,et al.  Personalized Medicine: Elusive Dream or Imminent Reality? , 2007, Clinical pharmacology and therapeutics.

[43]  M. Petzold,et al.  Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals. , 2007, Health policy.

[44]  W. Hellstrom,et al.  Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation , 2007, Therapeutics and clinical risk management.

[45]  D. Cutler.  The demise of the blockbuster? , 2007, The New England journal of medicine.

[46]  P. Levine,et al.  The global market for ADHD medications. , 2007, Health affairs.

[47]  K. Schulman,et al.  Cost of cancer care: issues and implications. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Rodney A Hayward,et al.  Narrative Review: Lack of Evidence for Recommended Low-Density Lipoprotein Treatment Targets: A Solvable Problem , 2006, Annals of Internal Medicine.

[49]  Claire Packer,et al.  International diffusion of new health technologies: A ten-country analysis of six health technologies , 2006, International Journal of Technology Assessment in Health Care.

[50]  L. Klareskog,et al.  Swedish registers to examine drug safety and clinical issues in RA , 2006, Annals of the rheumatic diseases.

[51]  G. Murdaca,et al.  Emerging biologic drugs for the treatment of rheumatoid arthritis. , 2005, Autoimmunity reviews.

[52]  Ezekiel J Emanuel,et al.  The patents-based pharmaceutical development process: rationale, problems, and potential reforms. , 2005, JAMA.

[53]  W. Kalow.  A pharmacogeneticist’s look at drug effects and the drug development process: an overview , 2005, Expert opinion on pharmacotherapy.

[54]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[55]  P. Crowther.  The party's over , 2005, Nature.

[56]  Claire Packer,et al.  Assessing the accuracy of forecasting: Applying standard diagnostic assessment tools to a health technology early warning system , 2004, International Journal of Technology Assessment in Health Care.

[57]  Elias Mossialos,et al.  Regulating Pharmaceuticals In Europe: Striving For Efficiency, Equity And Quality , 2004 .

[58]  M. Relling,et al.  Moving towards individualized medicine with pharmacogenomics , 2004, Nature.

[59]  Michel Wensing,et al.  What drives change? Barriers to and incentives for achieving evidence‐based practice , 2004, The Medical journal of Australia.

[60]  G. Mancia,et al.  European guidelines on cardiovascular disease prevention in clinical practice; Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts) , 2003, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[61]  F. Lichtenberg.  The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982–2001 , 2003, International Journal of Health Care Finance and Economics.

[62]  B. Beermann,et al.  Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications , 2003, BMJ : British Medical Journal.

[63]  R. Klein,et al.  Viagra: a success story for rationing? , 2002, Health affairs.

[64]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[65]  Deborah Grady,et al.  Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.

[66]  J. Drews.  Drug discovery: a historical perspective. , 2000, Science.

[67]  J. Reeves,et al.  Emerging Drug Targets for Antiretroviral Therapy , 2012, Drugs.

[68]  R. Bailey.  Management of Lower Urinary Tract Infections , 2012, Drugs.

[69]  C. Argoff,et al.  Use of antiepileptic drugs for nonepileptic conditions: Psychiatric disorders and chronic pain , 2011, Neurotherapeutics.

[70]  B. Wettermark,et al.  Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care. , 2009, Quality in primary care.

[71]  A. Schilder,et al.  Pneumococcal conjugate vaccines for preventing otitis media. , 2014, The Cochrane database of systematic reviews.

[72]  B. Hancock,et al.  Ten years of rituximab in NHL , 2009, Expert opinion on drug safety.

[73]  D. Niederwieser,et al.  The challenge of biosimilars. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[74]  M. Young,et al.  Health services research , 2008, Journal of General Internal Medicine.

[75]  C. Cowan,et al.  National health spending in 2006: a year of change for prescription drugs. , 2008, Health affairs.

[76]  J. Lau,et al.  Efficacy and Safety of Incretin Therapy in Type 2 Diabetes , 2007 .

[77]  B. Eriksson,et al.  Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. , 2006, Drugs.

[78]  青儀 健二郎,et al.  What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及 , 2006 .

[79]  C. Patterson,et al.  Diabetes Atlas (3rd edition) , 2006 .

[80]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice , 2004 .

[81]  Organización Mundial de la Salud.  Guidelines for ATC classification and DDD assignment , 1996 .